Category Industry Updates

Penn-BioNTech Innovative Therapeutics Seed Fund Unveils Its First Investment to Advance Therapeutic Innovation

Penn-BioNTech Innovative Therapeutics Seed Fund Reveals Its First Investment to Advance Therapeutic Innovation The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) has announced its investment in Emvena Therapeutics, a biotechnology company developing innovative messenger RNA (mRNA) medicines designed to deliver…

Read MorePenn-BioNTech Innovative Therapeutics Seed Fund Unveils Its First Investment to Advance Therapeutic Innovation

City of Hope Researchers Explore Microbiome-Based Approach to Prevent Bloodstream Infections

City of Hope and Collaborators Report Promising Phase 1 Results for SER-155, a 16-Strain Live Biotherapeutic Designed to Prevent Bloodstream Infections in Stem Cell Transplant Patients City of Hope®, one of the largest and most advanced cancer research and treatment…

Read MoreCity of Hope Researchers Explore Microbiome-Based Approach to Prevent Bloodstream Infections

International Ginseng Symposium Highlights Red Ginseng’s Anti-Aging Mechanisms

Research Presented at 14th International Symposium on Ginseng Highlights Red Ginseng’s Potential Benefits Against Age-Related Health Decline Clinical and preclinical research presented at the 14th International Symposium on Ginseng has highlighted the potential of Korean red ginseng (Panax ginseng C.A.…

Read MoreInternational Ginseng Symposium Highlights Red Ginseng’s Anti-Aging Mechanisms

REDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Arrowhead Pharmaceuticals’ REDEMPLO Gains NICE Recommendation for NHS Treatment of Familial Chylomicronaemia Syndrome in England and Wales Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) has received a positive funding recommendation from the National Institute for Health and Care Excellence (NICE), creating a new…

Read MoreREDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Incyte Presents New Data Advancing Gastrointestinal Cancer Pipeline at ESMO 2026

Incyte Presents Updated Clinical Data for KRAS G12D and TGFβR2×PD-1 Programs in Pancreatic and Colorectal Cancers Incyte has announced new clinical findings from its expanding oncology portfolio, highlighting the potential of two investigational cancer therapies in difficult-to-treat pancreatic and colorectal…

Read MoreIncyte Presents New Data Advancing Gastrointestinal Cancer Pipeline at ESMO 2026

Roche Reports Phase 3 Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy

Ionis and Roche Report Phase 3 Sefaxersen Data Showing Significant Proteinuria Reduction in IgA Nephropathy Ionis Pharmaceuticals, Inc. and its partner Roche have announced positive late-breaking results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with…

Read MoreRoche Reports Phase 3 Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy

Brenus Pharma Reports Promising Safety and T-Cell Activation Data for STC-1010, With Two Complete Responses in First-Line MSS Metastatic Colorectal Cancer

Brenus Pharma Reports Promising Phase Ia Results for STC-1010 in Metastatic Colorectal Cancer, With 57% Objective Response Rate Brenus Pharma, a clinical-stage biotechnology company developing innovative immunotherapies for cancer, has announced the first clinical results from the Phase Ia dose-escalation…

Read MoreBrenus Pharma Reports Promising Safety and T-Cell Activation Data for STC-1010, With Two Complete Responses in First-Line MSS Metastatic Colorectal Cancer

Nutromics Unveils World-First Real-Time Creatinine Data at ASN Kidney Week

Nutromics Demonstrates World-First Real-Time Creatinine Monitoring in Humans Using DNA-Based Wearable Sensors Nutromics has presented what it describes as world-first real-time measurements of creatinine in humans using DNA-based sensors, marking a significant development in the potential application of wearable technology…

Read MoreNutromics Unveils World-First Real-Time Creatinine Data at ASN Kidney Week

ViiV Healthcare Highlights Five-Year U.S. Real-World Evidence Supporting Cabenuva’s Long-Term Effectiveness and Treatment Persistence

ViiV Healthcare Reports Five-Year Real-World Evidence Supporting Long-Term Cabenuva Effectiveness in HIV Treatment ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, has announced new real-world evidence from the OPERA observational cohort evaluating…

Read MoreViiV Healthcare Highlights Five-Year U.S. Real-World Evidence Supporting Cabenuva’s Long-Term Effectiveness and Treatment Persistence